HIV/AIDS,Utilities,and Cost-Effectiveness Analysis: Stepping toward the Future

Abstract

Get full access to this article

View all access options for this article.

References

Tengs TO , Lin TH . A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making. 2002;22:475-481.

Revicki DA , Kaplan RM . Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life. Qual Life Res. 1993;2(6):477-487.

Tengs TO , Wallace A. One thousand health-related quality-of-life estimates. Med Care. 2000;38(6):583-637.

Weinstein MC , Goldie SJ , Losina E , et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Int Med. 2001;134(6):440-450.

Centers for Disease Control and Prevention . 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morb Mort Weekly Report. 1992;41(RR-17):1-13.

Drummond MF , Brandt A , Luce BR , et al. Standardizing economic evaluation methodologies in health care. Int J Technol Assess Health Care. 1993;9(1):26-36.

Freund DA , Dittus RS . Principles of pharmacoeconomic analysis of drug therapy. Pharmacoeconomics. 1992;1(1):20-29.

Lenert LA , Sturley A , Watson ME . iMPACT3: Internet-based development and administration of utility elicitation protocols. Med Decis Making. 2002;22:464-474.